BENGALURU (Reuters) – India’s government said on Thursday it has inked a deal with domestic vaccine maker Biological-E for 300 million COVID-19 vaccine doses for 15 billion rupees ($205.62 million).
The vaccine, which is currently undergoing phase-3 clinical trials, will likely to be available in the next few months, the health ministry said in a statement.
($1 = 72.9500 Indian rupees)
(Reporting by Rama Venkat in Bengaluru; Editing by Christopher Cushing)
